quinupristin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, streptogramins, protein-synthesis inhibitors, pristinamycin derivatives 2349 120138-50-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quinupristin mesilate
  • quinupristin
  • quinupristin mesylate
component of RP 59500
  • Molecular weight: 1022.23
  • Formula: C53H67N9O10S
  • CLOGP: 7.30
  • LIPINSKI: 3
  • HAC: 19
  • HDO: 4
  • TPSA: 231.20
  • ALOGS: -4.36
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.40 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.67 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.34 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.87 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 1999 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01FG02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Streptogramins
FDA CS M0022748 Streptogramins
FDA EPC N0000175502 Streptogramin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vancomycin resistant enterococcus indication 113727004
Streptococcus pyogenes infection indication 302809008
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Pyrexia of unknown origin off-label use 7520000
Hyperbilirubinemia contraindication 14783006 DOID:2741
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.19 acidic
pKa2 8.42 Basic
pKa3 4.85 Basic
pKa4 2.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4021184 VUID
N0000179688 NUI
D00852 KEGG_DRUG
4021184 VANDF
C0756081 UMLSCUI
CHEBI:8732 CHEBI
H8Q PDB_CHEM_ID
CHEMBL1200649 ChEMBL_ID
DB01369 DRUGBANK_ID
C113825 MESH_SUPPLEMENTAL_RECORD_UI
10798 IUPHAR_LIGAND_ID
6582 INN_ID
23OW28RS7P UNII
5388937 PUBCHEM_CID
229367 RXNORM
8299 MMSL
d04455 MMSL
007887 NDDF
116110009 SNOMEDCT_US
387015002 SNOMEDCT_US
441592000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Synercid HUMAN PRESCRIPTION DRUG LABEL 2 61570-260 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 26 sections
Synercid HUMAN PRESCRIPTION DRUG LABEL 2 61570-260 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 26 sections